Total Marrow Irradiation for Refractory Acute Leukemia
Status:
Completed
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Giving chemotherapy and total marrow irradiation before a donor umbilical cord
blood or hematopoietic stem cell transplant helps stop the growth of cancer cells. It may
also stop the patient's immune system from rejecting the donor's stem cells. When the healthy
stem cells from a donor are infused into the patient they may help the patient's bone marrow
make stem cells, red blood cells, white blood cells, and platelets. Sometimes the
transplanted cells from a donor can make an immune response against the body's normal cells.
Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from
happening.
PURPOSE: This phase I trial is studying the side effects and best dose of total marrow
irradiation when given together with combination chemotherapy and umbilical cord blood
hematopoietic stem cell transplant in treating patients with acute leukemia, acute myeloid
leukemia or multiple myeloma that did not respond to previous therapy.